SG11202004019SA - Compositions and methods for the treatment of eye disorders - Google Patents
Compositions and methods for the treatment of eye disordersInfo
- Publication number
- SG11202004019SA SG11202004019SA SG11202004019SA SG11202004019SA SG11202004019SA SG 11202004019S A SG11202004019S A SG 11202004019SA SG 11202004019S A SG11202004019S A SG 11202004019SA SG 11202004019S A SG11202004019S A SG 11202004019SA SG 11202004019S A SG11202004019S A SG 11202004019SA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- treatment
- methods
- eye disorders
- disorders
- Prior art date
Links
- 208000030533 eye disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201741041231 | 2017-11-17 | ||
| PCT/IB2018/057342 WO2019097318A1 (en) | 2017-11-17 | 2018-09-22 | Compositions and methods for the treatment of eye disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202004019SA true SG11202004019SA (en) | 2020-05-28 |
Family
ID=66540065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004019SA SG11202004019SA (en) | 2017-11-17 | 2018-09-22 | Compositions and methods for the treatment of eye disorders |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10933052B2 (en) |
| EP (1) | EP3651747A4 (en) |
| JP (1) | JP7006990B2 (en) |
| KR (1) | KR102349776B1 (en) |
| CN (1) | CN111372576A (en) |
| AU (1) | AU2018367909B2 (en) |
| BR (1) | BR112020009361A2 (en) |
| CA (1) | CA3081553C (en) |
| IL (1) | IL274234B2 (en) |
| MX (1) | MX389626B (en) |
| RU (1) | RU2761436C1 (en) |
| SG (1) | SG11202004019SA (en) |
| WO (1) | WO2019097318A1 (en) |
| ZA (1) | ZA202002066B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202103034UA (en) * | 2016-10-04 | 2021-05-28 | Cellix Bio Private Ltd | Compositions and methods for the treatment of xerostomia |
| MX392359B (en) * | 2017-11-17 | 2025-03-24 | Cellix Bio Private Ltd | Compounds, compositions and methods for treatment of eye disorders and skin diseases |
| BR112020015436A2 (en) * | 2018-02-05 | 2020-12-22 | Cellix Bio Private Limited | PHARMACEUTICAL COMPOSITION, PHYSICAL MIXTURE AND USE OF A COMPOSITION |
| MX2022006803A (en) | 2019-12-04 | 2022-09-19 | Restore Vision Llc | Ophthalmic formulations for the treatment of presbyopia. |
| US11400039B2 (en) * | 2020-01-16 | 2022-08-02 | James W. Hill | Changing eye color by gene transduction |
| WO2021240352A1 (en) * | 2020-05-26 | 2021-12-02 | Cellix Bio Private Limited | Pharmaceutical formulations of pilocarpine r-(+)-lipoate |
| WO2023052974A1 (en) * | 2021-09-29 | 2023-04-06 | Avaca Pharma Private Limited | Ocular compositions and methods for the treatment of ophthalmic diseases and disorders |
| US20250101009A1 (en) * | 2022-11-19 | 2025-03-27 | Iview Therapeutics, Inc. | Compounds, Compositions and Methods for Treatment of Age-Related Ocular Disorders |
| WO2025230326A1 (en) * | 2024-04-30 | 2025-11-06 | 주식회사태준제약 | Ophthalmic composition comprising pilocarpine |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL50250A (en) | 1975-08-27 | 1980-01-31 | Hydrophilics Int Inc | Sustained release compositions comprising slats of pharmaceutically acitve bases with polymers containing acid groups |
| US4076942A (en) | 1975-10-01 | 1978-02-28 | Merck & Co., Inc. | Crystalline dipilocarpinium pamoate |
| FR2424930A1 (en) | 1978-05-02 | 1979-11-30 | Inst Khim Drevesiny Akadem | NEW POLYMERS OF ALCOYL-1 (OXO-5 ALCOYL-4 TETRAHYDROFURYL-METHYL (3) -5) IMIDAZOLES AND CARBOXYALCOYL ETHERS OF POLYVINYL ALCOHOL, USED IN PARTICULAR AS M-CHOLINOMEDETIC AND PREPARATION AGENTS |
| US4977176A (en) | 1987-01-31 | 1990-12-11 | Sandoz Ltd. | Pilocarpine compounds which are used as pharmaceutical agents |
| NL8800099A (en) | 1987-01-31 | 1988-08-16 | Sandoz Ag | PILOCARPINE DERIVATIVES AND METHODS FOR PREPARING AND USING THESE DERIVATIVES. |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| JP2771257B2 (en) | 1989-06-22 | 1998-07-02 | 岩城製薬株式会社 | Preparation of imidazole derivatives |
| US5322942A (en) | 1991-06-03 | 1994-06-21 | Regents Of The University Of California | Synthesis of optically active lactones from L-aspartic acid and intermediates thereof |
| DE4222459C2 (en) | 1992-07-08 | 1995-09-14 | Sigma Tau Ind Farmaceuti | 3,9-disubstituted-spiro [5.5] undecane, a process for their preparation and pharmaceutical compositions containing them |
| US5783701A (en) | 1992-09-08 | 1998-07-21 | Vertex Pharmaceuticals, Incorporated | Sulfonamide inhibitors of aspartyl protease |
| US5723490A (en) | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
| IS2334B (en) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl protease inhibitor of a new class of sulfonamides |
| DE4334135A1 (en) | 1993-10-07 | 1995-04-13 | Merck Patent Gmbh | Process for the preparation of pilocarpine derivatives |
| IL113459A (en) | 1995-04-23 | 2000-07-16 | Electromagnetic Bracing System | Electrophoretic cuff apparatus |
| AU726522B2 (en) | 1995-09-01 | 2000-11-09 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
| US5811428A (en) | 1995-12-18 | 1998-09-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
| US6239180B1 (en) | 1995-11-08 | 2001-05-29 | The Regents Of The University Of California | Transdermal therapeutic device and method with capsaicin and capsaicin analogs |
| ATE263561T1 (en) | 1996-01-22 | 2004-04-15 | Fujisawa Pharmaceutical Co | THIAZOLYLBENZOFURAN DERIVATIVES AND THEIR USE AS SRS-A AND LEUCOTRIEN ANTAGONISTS |
| JP4395200B2 (en) | 1997-10-28 | 2010-01-06 | バンドー化学株式会社 | Skin patch sheet and method for producing substrate sheet therefor |
| US6329369B1 (en) | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
| US6103275A (en) | 1998-06-10 | 2000-08-15 | Nitric Oxide Solutions | Systems and methods for topical treatment with nitric oxide |
| DE19827732A1 (en) | 1998-06-22 | 1999-12-23 | Rottapharm Bv | Transdermal patch useful for hormone replacement therapy used for treatment of menopausal symptoms |
| US6222039B1 (en) | 1998-07-13 | 2001-04-24 | Hoffman-La Roche Inc. | Process for the preparation of chiral lactones |
| US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
| US6312716B1 (en) | 1999-05-10 | 2001-11-06 | Peierce Management Llc | Patch and method for transdermal delivery of bupropion base |
| TWI283669B (en) | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| US6974588B1 (en) | 1999-12-07 | 2005-12-13 | Elan Pharma International Limited | Transdermal patch for delivering volatile liquid drugs |
| MXPA03011082A (en) | 2001-06-05 | 2004-07-08 | Lilly Icos Llc | Pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione derivatives. |
| FR2832637B1 (en) * | 2001-06-07 | 2004-07-30 | Lefaix Marie Therese Droy | USE OF AN ANTIOXIDANT FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF EYE SURFACE CONDITIONS |
| IL166510A0 (en) | 2002-08-09 | 2006-01-15 | Nps Pharma Inc | 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5 |
| CA2499601A1 (en) | 2002-09-19 | 2004-04-01 | University Of Utah Research Foundation | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease |
| GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| DE10358539A1 (en) | 2003-12-15 | 2005-07-07 | Merck Patent Gmbh | carboxamide |
| US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| EP1737461B1 (en) | 2004-03-15 | 2012-12-12 | PTC Therapeutics, Inc. | Carboline derivatives useful in the inhibition of angiogenesis |
| US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
| EP1849781A1 (en) | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments |
| CN101522658A (en) * | 2006-06-16 | 2009-09-02 | 因迪基恩药物公司 | Metformin R- (+) lipoate as an antidiabetic agent for the control of diabetic hyperglycemia and diabetic complications |
| EP2044056B1 (en) | 2006-07-14 | 2012-08-22 | Novartis AG | Pyrimidine derivatives as alk-5 inhibitors |
| GB0724558D0 (en) * | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| CN101910153B (en) | 2008-01-11 | 2014-01-22 | 诺华股份有限公司 | Pyrimidines as Kinase Inhibitors |
| US8673970B2 (en) | 2008-02-21 | 2014-03-18 | Sequoia Pharmaceuticals, Inc. | HIV protease inhibitor and cytochrome p450 inhibitor combinations |
| US20090326004A1 (en) | 2008-06-03 | 2009-12-31 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| AU2009272486A1 (en) | 2008-07-18 | 2010-01-21 | Takeda Pharmaceutical Company Limited. | Benzazepine derivatives and their use as hstamine H3 antagonists |
| US20110091459A1 (en) | 2008-12-11 | 2011-04-21 | Auspex Pharmaceuticals, Inc. | Imidazole modulators of muscarinic acetylcholine receptor m3 |
| WO2010125416A1 (en) * | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
| US8470784B2 (en) * | 2009-08-24 | 2013-06-25 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
| US9173886B2 (en) | 2010-03-12 | 2015-11-03 | Trana Discovery, Inc. | Antiviral compounds and methods of use thereof |
| GB201007187D0 (en) | 2010-04-29 | 2010-06-09 | Iti Scotland Ltd | Ubiquitination modulators |
| ES3053320T3 (en) | 2010-06-03 | 2026-01-21 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| BR122014012788B1 (en) | 2010-06-23 | 2022-04-19 | Hanmi Science Co., Ltd | Fused pyrimidine derivatives, their uses, and pharmaceutical composition for inhibiting tyrosine kinase activity |
| CN102432598A (en) | 2010-09-29 | 2012-05-02 | 江苏恒瑞医药股份有限公司 | Tricyclic compound, preparation method thereof and pharmaceutical application thereof |
| WO2012065057A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| KR20130121903A (en) | 2010-11-30 | 2013-11-06 | 제넨테크, 인크. | Assays and biomarkers for lrrk2 |
| WO2012079032A2 (en) | 2010-12-09 | 2012-06-14 | Trana Discovery, Inc. | Compositions and methods of treating drug-resistant retroviral infections |
| US9388140B2 (en) | 2011-03-31 | 2016-07-12 | Bayer Intellectual Property Gmbh | Substituted benzimidazoles |
| US20140255392A1 (en) | 2011-04-06 | 2014-09-11 | Bayer Intellectual Property Gmbh | Substituted imidazopyridines and intermediates thereof |
| JP2012230356A (en) | 2011-04-15 | 2012-11-22 | Sumitomo Chemical Co Ltd | Compound, resist composition and method for producing resist pattern |
| GB201114448D0 (en) | 2011-08-22 | 2011-10-05 | Takeda Pharmaceutical | Compounds and their use |
| US20140228384A1 (en) | 2011-11-29 | 2014-08-14 | Genentech, Inc. | Assays and biomarkers for lrrk2 |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| CN104080773B (en) | 2012-01-28 | 2016-12-28 | 默克专利股份公司 | Nitrogen heterocyclic |
| WO2013144191A1 (en) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Substituted 2-amino-3-cyanopyridines as inhibitors of sodium-calcium exchange and use thereof for cardiovascular diseases |
| KR101586789B1 (en) * | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | Sustained-release lipid pre-concentrate of cationic pharmacologically active substance and pharmaceutical composition comprising the same |
| WO2014124141A1 (en) * | 2013-02-07 | 2014-08-14 | Mylari Banavara L | Metformin derivatives for treating diabetes |
| JP6449880B2 (en) | 2013-08-08 | 2019-01-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | New pyrazinamide compounds |
| WO2015082376A2 (en) | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Use of pi3k-inhibitors |
| WO2015082378A1 (en) | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| WO2015103577A1 (en) * | 2014-01-06 | 2015-07-09 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating dominant optic atrophy |
| WO2016002968A1 (en) | 2014-07-01 | 2016-01-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors |
| CN104387364B (en) * | 2014-12-15 | 2016-11-16 | 南京工业大学 | L-ornithine lipoic acid composite salt and preparation method and application thereof |
| SG10202103034UA (en) * | 2016-10-04 | 2021-05-28 | Cellix Bio Private Ltd | Compositions and methods for the treatment of xerostomia |
-
2018
- 2018-09-22 SG SG11202004019SA patent/SG11202004019SA/en unknown
- 2018-09-22 CA CA3081553A patent/CA3081553C/en active Active
- 2018-09-22 KR KR1020207017159A patent/KR102349776B1/en not_active Expired - Fee Related
- 2018-09-22 CN CN201880071277.XA patent/CN111372576A/en active Pending
- 2018-09-22 WO PCT/IB2018/057342 patent/WO2019097318A1/en not_active Ceased
- 2018-09-22 MX MX2020004666A patent/MX389626B/en unknown
- 2018-09-22 BR BR112020009361-0A patent/BR112020009361A2/en not_active IP Right Cessation
- 2018-09-22 AU AU2018367909A patent/AU2018367909B2/en not_active Ceased
- 2018-09-22 RU RU2020119218A patent/RU2761436C1/en active
- 2018-09-22 JP JP2020526481A patent/JP7006990B2/en not_active Expired - Fee Related
- 2018-09-22 EP EP18879678.3A patent/EP3651747A4/en not_active Withdrawn
-
2020
- 2020-02-13 US US16/790,492 patent/US10933052B2/en not_active Expired - Fee Related
- 2020-04-26 IL IL274234A patent/IL274234B2/en unknown
- 2020-05-04 ZA ZA2020/02066A patent/ZA202002066B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2761436C1 (en) | 2021-12-08 |
| IL274234B2 (en) | 2023-02-01 |
| JP2021503449A (en) | 2021-02-12 |
| NZ763688A (en) | 2021-10-29 |
| EP3651747A1 (en) | 2020-05-20 |
| US20200179343A1 (en) | 2020-06-11 |
| CA3081553C (en) | 2022-11-15 |
| AU2018367909A1 (en) | 2020-05-07 |
| MX389626B (en) | 2025-03-20 |
| BR112020009361A2 (en) | 2020-10-13 |
| MX2020004666A (en) | 2022-01-26 |
| CN111372576A (en) | 2020-07-03 |
| US10933052B2 (en) | 2021-03-02 |
| ZA202002066B (en) | 2021-07-28 |
| IL274234A (en) | 2020-06-30 |
| JP7006990B2 (en) | 2022-02-10 |
| IL274234B (en) | 2022-10-01 |
| WO2019097318A1 (en) | 2019-05-23 |
| KR20200089292A (en) | 2020-07-24 |
| AU2018367909B2 (en) | 2022-03-10 |
| CA3081553A1 (en) | 2019-05-23 |
| KR102349776B1 (en) | 2022-01-10 |
| EP3651747A4 (en) | 2020-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298689B1 (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| IL268406A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| ZA202002066B (en) | Compositions and methods for the treatment of eye disorders | |
| IL259861A (en) | Methods and compositions for the treatment of seizure-related disorders | |
| GB201405232D0 (en) | Apparatus and methods for the treatment of ocular disorders | |
| SG11202103033WA (en) | Compositions and methods for the treatment of presbyopia | |
| IL258032B (en) | Compounds and compositions for the treatment of ocular disorders | |
| IL275182A (en) | Compositions and methods for the treatment of metabolic conditions | |
| IL267229A (en) | Methods of treating ocular disorders | |
| IL263477A (en) | Compositions and methods for the treatment or prevention of oxalate-related disorders | |
| EP3429584A4 (en) | Compositions and methods for the treatment of presbyopia | |
| IL272121A (en) | Composition and methods for the treatment of myopia | |
| IL275985A (en) | Compositions and methods for treating retinal disorders | |
| IL269400A (en) | Drugs and compositions for the treatment of ocular disorders | |
| SG11201809811VA (en) | Compositions and methods for treatment of inflammation or infection of the eye | |
| SG11202012473UA (en) | Ophthalmic compositions and methods for the treatment of eye disorders | |
| EP3658218A4 (en) | Treatment of eye disorders | |
| IL282455A (en) | Methods and compositions for the treatment of secretory disorders | |
| ZA201806103B (en) | Compositions and methods for the treatment of sinus disease and disorders | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| HUE066000T2 (en) | (+)-azasetron for use in the treatment of ear disorders | |
| SG11201706952VA (en) | Compositions and methods for the treatment of epilepsy and neurological disorders | |
| ZA202004110B (en) | Compositions and methods for the treatment of metabolic conditions | |
| HK40006311A (en) | Compositions and methods for the treatment or prevention of oxalate-related disorders | |
| HK40009011A (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders |